NCT00116467CompletedPhase 2
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line
Cell Genesys4 sites in 1 country55 target enrollmentStarted: March 1, 2001Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 55
- Locations
- 4
Study Overview
Brief Summary
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months.
- •No prior therapy except leukapheresis or less than 72 hours of hydroxyurea.
Exclusion Criteria
- •Prior myelodysplastic disorder, or treatment-related leukemia.
- •Prior myeloproliferative disease.
- •Acute promyelocytic leukemia (APL).
- •Prior chemotherapy for a malignant or nonmalignant disorder.
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Completed
Phase 1
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple MyelomaMultiple MyelomaNCT00116441Cell Genesys22
Completed
Phase 2
Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's LymphomaLymphomaNCT00006241Fred Hutchinson Cancer Center
Completed
Phase 1
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by VaccinationChronic Lymphocytic LeukemiaNCT00442130Dana-Farber Cancer Institute27
Withdrawn
Phase 2
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid LeukemiaGraft Versus Host DiseaseLeukemiaNCT00004878Jonsson Comprehensive Cancer Center
Unknown
Phase 1
Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic EnterocolitisMyeloablative Chemotherapy Induced Bone Marrow AplasiaNeutropenic EnterocolitisNCT02145923Burnasyan Federal Medical Biophysical Center16